Experience in a UK cancer centre of weekly paclitaxel in the treatment of relapsed ovarian and primary peritoneal cancer

Gynecologic Oncology

Volumn 109, Issue 1, 2008, Pages 27-32

  Linch, M ^a   Stavridi, F ^a   Hook, J ^a   Barbachano, Y ^a   Gore, M ^a   Kaye, S B ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Ovarian cancer; Treatment free interval; Weekly paclitaxel

Indexed keywords

PACLITAXEL; TAXANE DERIVATIVE;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; CANCER SURVIVAL; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERANCE; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; HUMAN; HYPERSENSITIVITY; LETHARGY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NAIL INFECTION; NAUSEA; NEUTROPENIA; OVARY CANCER; PERIPHERAL NEUROPATHY; PERITONEUM CANCER; PRIORITY JOURNAL; RASH; SEPSIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR GROWTH; UNITED KINGDOM;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PACLITAXEL; PERITONEAL NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 40949110943     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2008.01.007     Document Type: Article

References (26)

1. Gottlieb J.A., and Drewinko B. Review of the current clinical status of platinum coordination complexes in cancer chemotherapy. Cancer Chemother Rep 59 (1975) 621-628
2. McGuire W.P., Hoskins W.J., Brady M.F., Kucera P.R., Partridge E.E., Look K.Y., et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334 1 (Jan 4 1996) 1-6
3. Piccart M.J., Bertelsen K., James K., Cassidy J., Mangioni C., Simonsen E., et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 92 9 (May 3 2000) 699-708
4. Eisenhauer E.A., Vermorken J.B., and van Glabbeke M. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients [see comments]. Ann Oncol 8 10 (Oct 1997) 963-968
5. Blackledge G., Lawton F., Redman C., and Kelly K. Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials. Br J Cancer 59 4 (Apr 1989) 650-653
6. Gore M.E., Fryatt I., Wiltshaw E., and Dawson T. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol 36 2 (Feb 1990) 207-211
7. Markman M., Rothman R., Hakes T., Reichman B., Hoskins W., Rubin S., et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 9 3 (Mar 1991) 389-393
8. Agarwal R., Linch M., and Kaye S.B. Novel therapeutic agents in ovarian cancer. Eur J Surg Oncol 32 8 (2006) 875-886
9. Bookman M.A. Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy. Oncologist 4 2 (1999) 87-94
10. Rowinsky E.K., and Donehower R.C. Paclitaxel (taxol). N Engl J Med 332 15 (Apr 13 1995) 1004-1014
11. Belotti D., Vergani V., Drudis T., Borsotti P., Pitelli M.R., Viale G., et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 2 11 (Nov 1996) 1843-1849
12. Kudoh K.K.Y., Kita T., et al. The effect of single weekly paclitaxel in heavily pretreated ovarian cancer patients and its antiangiogenic effects. Proc Am Soc Clin Oncol (2005) 5115
13. Lau D.H., Xue L., Young L.J., Burke P.A., and Cheung A.T. Paclitaxel (Taxol): an inhibitor of angiogenesis in a highly vascularized transgenic breast cancer. Cancer Biother Radiopharm 14 1 (Feb 1999) 31-36
14. Markman M., Hall J., Spitz D., Weiner S., Carson L., Van Le L., et al. Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer. J Clin Oncol 20 9 (May 1 2002) 2365-2369
15. Kaern J., Baekelandt M., and Trope C.G. A phase II study of weekly paclitaxel in platinum and paclitaxel-resistant ovarian cancer patients. Eur J Gynaecol Oncol 23 5 (2002) 383-389
16. Green M.C., Buzdar A.U., Smith T., Ibrahim N.K., Valero V., Rosales M.F., et al. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol 23 25 (Sep 1 2005) 5983-5992
17. Rosenberg P., Andersson H., Boman K., Ridderheim M., Sorbe B., Puistola U., et al. Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum. Acta Oncol 41 5 (2002) 418-424
18. Fennelly D., Aghajanian C., Shapiro F., O'Flaherty C., McKenzie M., O'Connor C., et al. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol 15 1 (Jan 1997) 187-192
19. Loffler T.M., Freund W., Lipke J., and Hausamen T.U. Schedule- and dose-intensified paclitaxel as weekly 1-hour infusion in pretreated solid tumors: results of a phase I/II trial. Semin Oncol 23 6 Suppl 16 (Dec 1996) 32-34
20. 2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. Gynecol Oncol 101 3 (Jun 2006) 436-440
21. Rustin G.J. Use of CA-125 to assess response to new agents in ovarian cancer trials. J Clin Oncol 21 10 Suppl (May 15 2003) 187-193
22. Rustin G.J., Nelstrop A.E., Bentzen S.M., Bond S.J., and McClean P. Selection of active drugs for ovarian cancer based on CA-125 and standard response rates in phase II trials. J Clin Oncol 18 8 (Apr 2000) 1733-1739
23. Kita T., Kikuchi Y., Takano M., Suzuki M., Oowada M., Konno R., et al. The effect of single weekly paclitaxel in heavily pretreated patients with recurrent or persistent advanced ovarian cancer. Gynecol Oncol 92 3 (Mar 2004) 813-818
24. Dunder I., Berker B., Atabekoglu C., and Bilgin T. Preliminary experience with salvage weekly paclitaxel in women with advanced recurrent ovarian carcinoma. Eur J Gynaecol Oncol 26 1 (2005) 79-82
25. Boruta II D.M., Fowler Jr. W.C., Gehrig P.A., Boggess J.F., Walton L.A., and Van Le L. Weekly paclitaxel infusion as salvage therapy in ovarian cancer. Cancer Invest 21 5 (2003) 675-681
26. Ghamande S., Lele S., Marchetti D., Baker T., and Odunsi K. Weekly paclitaxel in patients with recurrent or persistent advanced ovarian cancer. Int J Gynecol Cancer 13 2 (Mar-Apr 2003) 142-147